Jesús Loarce (@jesusloarce) 's Twitter Profile
Jesús Loarce

@jesusloarce

Rheumatology, Ramón y Cajal University Hospital.
Interested in idiopathic inflammatory myopathy and interstitial lung diseases associated to CTD.

ID: 1111658558263840768

calendar_today29-03-2019 15:57:08

1,1K Tweet

839 Followers

286 Following

Dr Ai Lyn Tan (@drailyntan) 's Twitter Profile Photo

Neutrophils pivotal in #Behcet's syndrome pathogenesis↔️Target for therapy ▶️Infliximab superior to cyclophosphamide for induction ▶️Adalimumab superior to cyclosporin to reduce uveitis relapse via Matteo Piga #EULAR2025

Neutrophils pivotal in #Behcet's syndrome pathogenesis↔️Target for therapy

▶️Infliximab superior to cyclophosphamide for induction
▶️Adalimumab superior to cyclosporin to reduce uveitis relapse

via <a href="/RMD_clinic/">Matteo Piga</a> #EULAR2025
Jesús Loarce (@jesusloarce) 's Twitter Profile Photo

Interesting work on the risk of progression of systemic sclerosis interstitial lung disease (ILD) ➡️ FVC decline in a 12 month period does not predict ILD progression in the next period ⚠️ Nevertheless, FVC decline is associated with mortality pubmed.ncbi.nlm.nih.gov/40381640/

Rheumatology & Rheumatology Advances in Practice (@rheumjnl) 's Twitter Profile Photo

New systematic review by Siniša Savić et al. characterises the complete phenotypic spectrum of VEXAS syndrome. ➡️These findings will facilitate earlier diagnosis, inform monitoring strategies, and guide future research priorities. ➡️bit.ly/40gp76A

New systematic review by <a href="/sinisauksav/">Siniša Savić</a> et al. characterises the complete phenotypic spectrum of VEXAS syndrome.

➡️These findings will facilitate earlier diagnosis, inform monitoring strategies, and guide future research priorities.

➡️bit.ly/40gp76A
Dr. John Cush (@rheumnow) 's Twitter Profile Photo

First FcRn inhibitor in #IIM: In #ALKIVIA, SC efgartigimod PH20 improved TIS vs placebo at 24wks (50.45 vs 35.65, p=0.0004), with faster time to TIS≥20 (30 vs 71.5d) & TIS≥40 (113d vs NE). More major responders too (TIS>60: 34% vs 9.5%). #EULAR2025 #OP0002

First FcRn inhibitor in #IIM: In #ALKIVIA, SC efgartigimod PH20 improved TIS vs placebo at 24wks (50.45 vs 35.65, p=0.0004), with faster time to TIS≥20 (30 vs 71.5d) &amp; TIS≥40 (113d vs NE). More major responders too (TIS&gt;60: 34% vs 9.5%).

 #EULAR2025 #OP0002
Dr. John Cush (@rheumnow) 's Twitter Profile Photo

ICYMI: Consensus Against Interventional Injections for Chronic Spinal Pain BMJ has published a clinical practice guideline resulting from the work of an international, multidisciplinary panel addressing chronic spine pain (≥3 months duration) not associated with cancer or

ICYMI: Consensus Against Interventional Injections for Chronic Spinal Pain 

BMJ has published a clinical practice guideline resulting from the work of an international, multidisciplinary panel addressing chronic spine pain (≥3 months duration) not associated with cancer or
Reumatología Ramón y Cajal (@reumatologiaryc) 's Twitter Profile Photo

Nuestra enfermera Patricia García, habla del abordaje en la cura de las úlceras en pacientes con esclerosis sistémica. Fundamental el papel de la enfermera especializada en el cuidado de los pacientes.

Cristina Macía (@reumacia) 's Twitter Profile Photo

Primera revisión sistemática de la literatura 📚 de George Fragoulis et al. sobre la combinación de FAMEb en enfermedades inmunomediadas (¡1200 pacientes!). Combinaciones más frecuentes: TNFi+IL/23i, JAKi+bDMARDs, y vedolizumab+TNFi. Acceso abierto 🔑 sciencedirect.com/science/articl…

Primera revisión sistemática de la literatura 📚 de <a href="/FragoulisGeorge/">George Fragoulis</a> et al. sobre la combinación de FAMEb en enfermedades inmunomediadas (¡1200 pacientes!). 

Combinaciones más frecuentes: TNFi+IL/23i, JAKi+bDMARDs, y vedolizumab+TNFi.

Acceso abierto 🔑 sciencedirect.com/science/articl…
A. E. Esclerodermia (@aeesclerodermia) 's Twitter Profile Photo

🎥¡Seguimos difundiendo el conocimiento! Ya puedes ver la ponencia: “¿Qué hago con mis úlceras y calcinosis?”, a cargo de la Sra. Patricia García, enfermera de Reumatología Ramón y Cajal del Hospital Ramón y Cajal. 👉youtube.com/watch?v=8PNI0d… #aeecongreso2025 #Esclerodermia #Reumatología

🎥¡Seguimos difundiendo el conocimiento!
Ya puedes ver la ponencia: “¿Qué hago con mis úlceras y calcinosis?”, a cargo de la Sra. Patricia García, enfermera de <a href="/ReumatologiaRyC/">Reumatología Ramón y Cajal</a> del Hospital Ramón y Cajal. 

👉youtube.com/watch?v=8PNI0d…

#aeecongreso2025 #Esclerodermia #Reumatología
Dr. John Cush (@rheumnow) 's Twitter Profile Photo

Novartis announced top line results of its ianalumab (VAY736;B cell inhibitor) in primary Sjögren’s dz. 2 RCTs, NEPTUNUS-1 and NEPTUNUS-2, met met primary endpoints w/ statistically significant improvements in disease activity in Sjögren’s patients. buff.ly/c6COFPw

Novartis announced top line results of its ianalumab (VAY736;B cell inhibitor) in primary Sjögren’s dz. 2 RCTs, NEPTUNUS-1 and NEPTUNUS-2, met met primary endpoints w/ statistically significant improvements in disease activity in Sjögren’s patients. buff.ly/c6COFPw
Jesús Loarce (@jesusloarce) 's Twitter Profile Photo

Two recent studies on rheumatoid arthritis associated interstitial lung disease (RA-ILD): ▶️ Review of lung ultrasound as a screening tool in RA-ILD pubmed.ncbi.nlm.nih.gov/40643573/ ▶️ Peripheral biomarker signatures in RA-ILD: analysis of the VARA registry pubmed.ncbi.nlm.nih.gov/40033001/

Jesús Loarce (@jesusloarce) 's Twitter Profile Photo

Subanalysis of the proDerm study: ▶️Predictors of response to IVIG: ⬆️cutaneous activity and anti-TIF1-γ➕ pubmed.ncbi.nlm.nih.gov/39918968/ ▶️Efficacy of IVIG on systemic manifestations: 🔝Skeletal, also in pulmonary, gastrointestinal and constitutional domains pubmed.ncbi.nlm.nih.gov/40616720/

Jesús Loarce (@jesusloarce) 's Twitter Profile Photo

Two recent articles ➡️ lung trasplant results in patients with connective tissue disease associated interstitial lung disease #ILD: ▶️Observational study, Johns Hopkins Hospital cohort, focused in #myositis pubmed.ncbi.nlm.nih.gov/40808826/ ▶️Systematic review pubmed.ncbi.nlm.nih.gov/40426174/

Jesús Loarce (@jesusloarce) 's Twitter Profile Photo

Update of the ATS/ERS Multidisciplinary Classification of the Interstitial Pneumonias🫁 ▶️Histological and radiological patterns (idiopathic, secondary) ▶️Interstitial vs alveolar ▶️New pattern (BIP), reclassification of old patterns (DIP➡️AMP, AIP➡️DAD) publications.ersnet.org/content/erj/ea…

Update of the ATS/ERS Multidisciplinary Classification of the Interstitial Pneumonias🫁
▶️Histological and radiological patterns (idiopathic, secondary)
▶️Interstitial vs alveolar 
▶️New pattern (BIP), reclassification of old patterns (DIP➡️AMP, AIP➡️DAD)

publications.ersnet.org/content/erj/ea…
Jesús Loarce (@jesusloarce) 's Twitter Profile Photo

Systematic review/meta-analysis ➡️treatments for rheumatoid arthritis interstitial lung disease 💊 Methotrexate ⬇️ mortality, FVC and composite progression 💊 Abatacept⬇️ HRCT and composite progression 💊 RTX/MMF/JAKi stabilize FVC #rheumatology #RAILD sciencedirect.com/science/articl…

Cristina Macía (@reumacia) 's Twitter Profile Photo

Espero veros a todos siguiendo el #ACR25 review 🇺🇸 de Soc.Esp.Reumatología que tengo el gusto de coordinar Revisores TOP 🔝 - Roxana González ➡️ AR - María Jesús Montesa ➡️ EspA - Ana Lois ➡️ LES, Sjögren, esclerodermia - Jesús Loarce ➡️ vasculitis, miopatías - LuisCT ➡️ miscelánea

Espero veros a todos siguiendo el #ACR25 review 🇺🇸 de <a href="/SEReumatologia/">Soc.Esp.Reumatología</a> que tengo el gusto de coordinar  

Revisores TOP 🔝 
- <a href="/RoxOsler/">Roxana González</a> ➡️ AR
- <a href="/montesa_maria/">María Jesús Montesa</a> ➡️ EspA
- <a href="/a_lois_/">Ana Lois</a> ➡️ LES, Sjögren, esclerodermia
- <a href="/JesusLoarce/">Jesús Loarce</a> ➡️ vasculitis, miopatías
- <a href="/LuisCorTar/">LuisCT</a> ➡️ miscelánea
Cristina Macía (@reumacia) 's Twitter Profile Photo

Primer día de resúmenes #ACReview25 de Soc.Esp.Reumatología que tengo el gusto de coordinar ¡Equipazo de revisores TOP! 🔝 Link 👉🏻 acr-review.ser.es

Primer día de resúmenes #ACReview25 de <a href="/SEReumatologia/">Soc.Esp.Reumatología</a> que tengo el gusto de coordinar

¡Equipazo de revisores TOP! 🔝

Link 👉🏻 acr-review.ser.es
David Liew (@drdavidliew) 's Twitter Profile Photo

Screening for ILD in RA patients: CXR and PFTs by themselves are close to a waste of time. When it comes to screening (high-risk) RA patients, it’s HRCT (or lung USS) or nothing really. (in keeping with EULAR, ACR guidelines) #ACR25 ABST1335 Dr. John Cush

Screening for ILD in RA patients:
CXR and PFTs by themselves are close to a waste of time.

When it comes to screening (high-risk) RA patients, it’s HRCT (or lung USS) or nothing really.
(in keeping with EULAR, ACR guidelines)

#ACR25 ABST1335 <a href="/RheumNow/">Dr. John Cush</a>
Cristina Macía (@reumacia) 's Twitter Profile Photo

Segundo día de resúmenes #ACReview25 de Soc.Esp.Reumatología que tengo el gusto de coordinar ¡Equipazo de revisores TOP! 🔝 Link 👉🏻 acr-review.ser.es

Segundo día de resúmenes #ACReview25 de <a href="/SEReumatologia/">Soc.Esp.Reumatología</a> que tengo el gusto de coordinar

¡Equipazo de revisores TOP! 🔝

Link 👉🏻 acr-review.ser.es
Cristina Macía (@reumacia) 's Twitter Profile Photo

Tercer día de resúmenes #ACReview25 de Soc.Esp.Reumatología que tengo el gusto de coordinar ¡Equipazo de revisores TOP! 🔝 Link 👉🏻 acr-review.ser.es

Tercer día de resúmenes #ACReview25 de <a href="/SEReumatologia/">Soc.Esp.Reumatología</a> que tengo el gusto de coordinar

¡Equipazo de revisores TOP! 🔝

Link 👉🏻 acr-review.ser.es